| Name | Title | Contact Details |
|---|
TytoCare Ltd. is a consumer-focused telehealth company, offering state-of-the-art, patented devices and platform that empower anyone, anywhere and anytime to perform a variety of medical examinations and seamlessly consult with a clinician. The company was founded by Dedi Gilad, Ofer Tzadik and industry experts in 2012. Investors include OrbiMed Advisors, Walgreens, Cambia Health Solutions, Fosun Pharma, LionBird, Teuza VC and others.
Vidant Health is a system of care. It includes Vidant Medical Center, the region`s only Level 1 trauma center, community hospitals, physician practices and partners who collaborate with us to enhance the quality of life for the people and communities we serve, touch and support. Vidant Health is affiliated with the Brody School of Medicine at East Carolina University and provides a continuum of care that addresses wellness, prevention and community health issues as well as acute care, post-acute care, home health and hospice.
Insitu Technologies Inc is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Universal Nutrition is a New Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.